Abcam plc (ABCM) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cambridge, United Kingdom. El CEO actual es Alan Thomas Hirzel BS,.
ABCM tiene fecha de IPO 2020-10-22, 1,760 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $5.52B.
Abcam plc is a life science company headquartered in Cambridge, United Kingdom, specializing in the identification, development, and distribution of reagents and tools for scientific research, diagnostics, and drug discovery. The company's product portfolio includes primary and secondary antibodies, conjugated antibodies, immunoassays, proteins and peptides, edited cell lines, and complementary research tools such as cellular activity kits and cell signaling pathway tools. Abcam serves a diverse customer base encompassing academic institutions, research institutes, and commercial entities in the pharmaceutical, biotechnology, and diagnostics sectors. With established operations across the Americas, Europe, Asia Pacific, and other regions, the company distributes its products primarily through online channels. Founded in 1998, Abcam has established itself as a key supplier of essential scientific research materials globally.
